Navigation Links
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Date:1/28/2008

FAIRFIELD, N.J., Jan. 28 /PRNewswire/ -- Arno Therapeutics, Inc., a privately held drug development company, announced that it has entered into worldwide, exclusive license agreements with The Ohio State University ("OSU") for the rights to commercially develop novel, orally available, targeted therapies for cancer.

Pursuant to the license agreements, Arno acquired the rights to several small molecules for the treatment of cancer, including OSU-03012 (NSC D728209) and OSU-HDAC42 (NSC D736012). Both agents were developed by Ching-Shih Chen, Ph.D., a professor of pharmacy and internal medicine at Ohio State and a researcher in OSU's Comprehensive Cancer Center.

OSU-03012 is a PDK-1 inhibitor that targets the Akt pathway, and also possesses activity in alternate pathways to target apoptosis and angiogenesis. Preclinical data have demonstrated activity in multiple tumor types and synergistic activity with other agents including Avastin(R), Herceptin(R), Tarceva(R), Gleevec(R) and tamoxifen.

OSU-HDAC42 is a broad spectrum histone-deacetylase inhibitor which possesses additional mechanisms as well. In preclinical studies OSU-HDAC42 has demonstrated greater potency and a competitive profile in solid and liquid tumors when compared with vorinostat (SAHA), the leading marketed compound in the class.

"We are extremely pleased to be developing these two exciting and novel molecules for the treatment of cancer patients," said Scott Z. Fields, M.D., President and CMO of Arno. "We look forward to moving these molecules into the clinic and to hopefully bringing their benefits to patients who need them as soon as possible."

"The out-licensing of these two very important molecularly targeted oncology compounds to Arno Therapeutics is a significant milestone for Ohio State," said Dr. Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center and CEO of The James Cancer Hospital and Solove Research Institute. "These a
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
4. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
5. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
6. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
7. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
8. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
9. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Its that time again for the half-year roundup of stock market ... you recall the results from the first quarter, it was pretty ... percent , Nasdaq National Market down 8 percent , Nasdaq Biotech ... isnt a great trend. As you can see below, the results ...
... International, a supplier of automatic identification and data collection ... 4.0 of their NiceLabel software. , ,The new versions ... radio frequency identification (RFID) tags, as well as an ... with Windows programs such as Microsoft Access, Windows Event ...
... As NASA works to get the Space Shuttle Discovery ... be monitored by NASA flight surgeons using GE Healthcare's ... health information will enable NASA to monitor and track the ... the sharing also of information with experts located outside NASA's ...
Cached Biology Technology:Midwest large cap life sciences mostly outperform market 2Midwest large cap life sciences mostly outperform market 3
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the wind, but a new study in the October 14th ... confirms that they are anything but drifters. A previous ... evidence that Silver Y moths rely on a sophisticated internal ... destination within a matter of days. Now, the research team ...
... mouse heart has an astounding capacity to regenerate, ... The research, published by Cell Press in the ... Cell , describes the previously unrecognized potential of ... compensatory proliferation of healthy cells. Disorders of ...
... why people who eat more fruit and vegetables may gain ... that a fragment released from pectin, found in all fruits ... 3 (Gal3), a protein that plays a role in all ... effects of foods are based on population studies," says Professor ...
Cached Biology News:Migratory moths may hitch their rides, but they're anything but drifters 2Embryonic heart exhibits impressive regenerative capacity 2Pectin power 2
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: